Comprehensive analysis of the prognosis and immune effect of the oncogenic protein Four Jointed Box 1

Sep 24, 2026

Upload by Mia

Comprehensive analysis examines the oncogenic gene Four Jointed Box 1 (FJX1) to clarify its biological function and immune relevance, with the aim of identifying potential cancer immunotherapy targets. Using TCGA and GTEx expression datasets, the study evaluates copy number alterations, mutations, and DNA methylation via cBioPortal, and relates FJX1 to immune infiltration and immune-related or immunosuppressive pathways through ImmuCellAI and TIMER2. Tumor mutational burden and microsatellite instability, plus immunotherapy response and IC50, are assessed with TCGA pan-cancer data and IMvigor210/GDSC, followed by colon cancer in vitro validation. Results show high FJX1 predicts poor prognosis, links to macrophage abundance and immunosuppression, associates with reduced immunotherapy effectiveness, and its knockdown decreases proliferation and migration.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Background

Methods

Results

Conclusion

Introduction

TYPE Original Research PUBLISHED 30 May 2023 DOI 10.3389/fonc.2023.1170482 OPEN ACCESS EDITED BYEsra Akbay, University of Texas Southwestern Medical Center, United States REVIEWED BY Shoib Sarwar Siddiqui, University of Hertfordshire, United Kingdom Wei Kang, The Chinese University of Hong Kong, China *CORRESPONDENCE Kangmin Zhuang [zkm1002@126.com](zkm1002@126.com)[ ](zkm1002@126.com)Side Liu [liuside2011@163.com](liuside2011@163.com)[ ](liuside2011@163.com)Yali Zhang [zyl41531@163.com](zyl41531@163.com) †These authors have contributed equally to this work and share ﬁrst authorship RECEIVED 21 February 2023 ACCEPTED 02 May 2023 PUBLISHED 30 May 2023 CITATION Huang M, Guo T, Meng Y, Zhou R, Xiong M, Ding J, Zhang Y, Liu S and Zhuang K (2023) Comprehensive analysis of the prognosis and immune effect of the oncogenic protein Four Jointed Box 1 . Front. Oncol. 13:1170482 . doi: 10.3389/fonc.2023.1170482 COPYRIGHT © 2023 Huang, Guo, Meng, Zhou, Xiong, Ding, Zhang, Liu and Zhuang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Comprehensive analysis of the prognosis and immune effect of the oncogenic protein Four Jointed Box 1 Mei Huang 1†, Tian Guo 1†, Yan Meng 1†, Ruling Zhou 1†, Man Xiong 1, Jian Ding 1, Yali Zhang 1*, Side Liu 1,2,3* and Kangmin Zhuang 1* 1Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, 2 Pazhou Lab, Guangzhou, Guangdong, China, 3 Department of Gastroenterology, Zhuhai People’s Hospital (Zhuhai Hospital Afﬁliated With Jinan University), Zhuhai, Guangdong, China Background: The Four Jointed Box 1 (FJX1) gene has been implicated in the upregulation of various cancers, highlighting its crucial role in oncology and immunity. In order to better understand the biological function of FJX1 and identify new immunotherapy targets for cancer, we conducted a comprehensive analysis of this gene. Methods: We analyzed the expression proﬁles and prognostic value of FJX1 using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) . Copy number alterations (CNAs), mutations, and DNA methylation were analyzed through c BioPortal. The Immune Cell Abundance Identiﬁer (ImmuCellAI) was used to examine the correlation between FJX1 expression and immune cell inﬁltration. The relationship between FJX1 expression and immune-related genes and immunosuppressive pathway-related genes was analyzed using The Tumor Immune Estimation Resource version 2 (TIMER2) . Tumor mutational burden (TMB) and microsatellite instability (MSI) were obtained from TCGA pan-cancer data. The effect of immunotherapy and the IC50 were assessed using IMvigor210CoreBiologies and Genomics For Drug Sensitivity in Cancer (GDSC) . Finally, we evaluated the impact of FJX1 on colon cancer cell proliferation and migration through in vitro functional experiments. Results: Our study indicated that FJX1 expression was high in most cancers and was signiﬁcantly associated with poor prognosis. High FJX1 expression was also linked to signiﬁcant alterations in CNA, DNA methylation, TMB, and MSI. Positive correlations were found between FJX1 expression and tumor-associated macrophages (TAMs) and with immune-related genes such as TGFB1 and IL- 10 and immunosuppressive pathway-related genes such as TGFB1 and WNT1 . On the other hand, FJX1 expression showed a negative relationship with CD8+ T cells. Furthermore, high FJX1 expression led to reduced effectiveness of immunotherapy and drug resistan

FAQs

What is the main purpose of analyzing FJX1 in this study?

To clarify FJX1’s biological function and immune-related roles and to identify potential new immunotherapy targets for cancer.

Which datasets and tools are used to analyze FJX1?

Expression profiles and prognostic value are analyzed using TCGA and GTEx; CNAs, mutations, and DNA methylation are examined via cBioPortal, while immune infiltration correlations use ImmuCellAI and TIMER2. Tumor mutational burden and MSI are taken from TCGA pan-cancer data, and immunotherapy effects and IC50 are assessed using IMvigor210CoreBiologies and GDSC.

What key findings link FJX1 to prognosis, immunity, and treatment response?

High FJX1 expression is associated with poor prognosis and with alterations in CNA, DNA methylation, TMB, and MSI; it correlates positively with TAMs and immunosuppressive pathways, negatively with CD8+ T cells, and reduces immunotherapy effectiveness and increases drug resistance.

Sep 24, 2026

Upload by Mia